A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor

• Status: Not yet recruiting
• Trial end date: 2024-05-30
• Target enrollment: 0
• Participant gender: All

Summary

It is a single-arm, open-label, multicenter, phase I trial,aiming at exploring the MTD and RP2D of Linperlisib combination with Camrelizumab in treating patients with advanced solid tumor,observing the preliminary efficacy.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd.

Criteria

Inclusion Criteria:

• 18 years old≦age≦75 years old;

• Histologically or cytologically confirmed locally advanced or metastatic malignant solid tumors；

• Failure of previous standard treatment (sufficient prior treatment and no better treatment than participating in clinical research);

• Qualified basic organ function and body condition;

• The expected survival is greater than 3 months;

• Adequate washout period.

Exclusion Criteria:

• Prior allergy to study drug components;

• Chronic metabolic diseases that are poorly controlled by medication;

• Brain metastases, infection, hemorrhage, autoimmune disease or cardiovascular disease, whichever is in active state;

• Digestive tract diseases that affect absorption of studied drugs.